Приказ основних података о документу

dc.creatorImenez Silva, Pedro H.
dc.creatorUnwin, Robert
dc.creatorHoorn, Ewout J.
dc.creatorOrtiz, Alberto
dc.creatorTrepiccione, Francesco
dc.creatorNielsen, Rikke
dc.creatorPešić, Vesna
dc.creatorHafez, Gaye
dc.creatorFouque, , Denis
dc.creatorMassy, Ziad A.
dc.creatorDe Zeeuw, Chris I.
dc.creatorCapasso, Giovambattist
dc.creatorWagner, Carsten
dc.date.accessioned2022-01-28T09:06:08Z
dc.date.available2022-01-28T09:06:08Z
dc.date.issued2022
dc.identifier.issn0931-0509
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/4028
dc.description.abstractMetabolic acidosis, defined as a plasma or serum bicarbonate concentration <22 mmol/L, is a frequent consequence of chronic kidney disease (CKD) and occurs in ~10-30% of patients with advanced stages of CKD. Likewise, in patients with a kidney transplant, prevalence rates of metabolic acidosis range from 20% to 50%. CKD has recently been associated with cognitive dysfunction, including mild cognitive impairment with memory and attention deficits, reduced executive functions and morphological damage detectable with imaging. Also, impaired motor functions and loss of muscle strength are often found in patients with advanced CKD, which in part may be attributed to altered central nervous system (CNS) functions. While the exact mechanisms of how CKD may cause cognitive dysfunction and reduced motor functions are still debated, recent data point towards the possibility that acidosis is one modifiable contributor to cognitive dysfunction. This review summarizes recent evidence for an association between acidosis and cognitive dysfunction in patients with CKD and discusses potential mechanisms by which acidosis may impact CNS functions. The review also identifies important open questions to be answered to improve prevention and therapy of cognitive dysfunction in the setting of metabolic acidosis in patients with CKD.
dc.publisherOxford University Press
dc.relationCOST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
dc.relationSwiss National Science Foundation–financed NCCR Kidney.
dc.relationFIS/Fondos FEDER [PI18/01366, PI19/00588, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009)], Sociedad Española de Nefrología, FRIAT and Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM.
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceNephrology Dialysis Transplantation
dc.subjectacidosis
dc.subjectchronic kidney disease
dc.subjectcognitive dysfunction
dc.subjectklotho
dc.subjectmotor function
dc.titleAcidosis, cognitive dysfunction and motor impairments in patients with kidney disease
dc.typearticle
dc.rights.licenseBY-NC
dc.citation.volume37
dc.citation.issuesupplement 2
dc.citation.spageii4
dc.citation.epageii12
dc.citation.rankM21
dc.identifier.wos000740945100002
dc.identifier.doi10.1093/ndt/gfab216
dc.identifier.scopus2-s2.0-85123025417
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/9399/Acidosis_cognitive_dysfunctio_pub_2022.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу